Home/Pipeline/mRNA-based Broad Flu Vaccine

mRNA-based Broad Flu Vaccine

Influenza prevention

Pre-clinicalActive

Key Facts

Indication

Influenza prevention

Phase

Pre-clinical

Status

Active

Company

Micron Biomedical

About Micron Biomedical

Micron Biomedical is a private, clinical-stage biotech based in Atlanta, GA, founded in 2013. The company is advancing a novel dissolvable microarray platform for the needle-free delivery of vaccines and therapeutics, designed to be painless, thermostable, and suitable for self-administration. With significant non-dilutive grant funding and partnerships with major global health organizations, Micron is progressing multiple programs, including vaccines for rotavirus, measles/rubella, and influenza, into clinical trials. Its technology addresses critical challenges in global health, including cold chain dependence, need for trained personnel, and vaccine hesitancy.

View full company profile

Therapeutic Areas

Infectious Disease Global Health/Vaccines

Other Influenza prevention Drugs

Drug	Company	Phase	Status
CaPtivaX Nasal Influenza Vaccine	CaPtivate Pharmaceuticals	Pre-clinical	Active
Next-Generation Influenza Vaccines	Fluart Innovative Vaccines	Not Disclosed	Active
HD-MAP Influenza Vaccine	Vaxxas	Phase 2/3	Active
IRT Platform (e.g., Influenza)	Biological Mimetics	Research/Pre-clinical	Active
Replicon RNA Influenza Vaccine	BIKEN Group	Preclinical/Development	Partnership Development with VLPT Japan and Denka
Innovative Influenza Vaccine	Livzon Pharmaceutical	Phase 1	Completed patient enrollment in Phase I
CS-2606 mRNA Multi-valent Influenza Vaccine	CanSino Biologics	Pre-clinical	Active